Q-omics provides the consensus-scored TH2LCRR profile across patient tissues and cancer cell-line models. TH2LCRR expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TH2LCRR is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TH2LCRR RNA expression shows 18,226 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, KIRC, and UVM as cancer lineages where TH2LCRR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TH2LCRR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TH2LCRR survival associations across molecular data types. TH2LCRR RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TH2LCRR RNA expression–survival associations across cancer types. High TH2LCRR expression shows unfavorable associations in COAD, ACC, CHOL and KIRC, but favorable associations in UCS and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TH2LCRR RNA expression.
This table summarizes TH2LCRR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TH2LCRR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TH2LCRR shows higher tumor expression in KIRC, CHOL, HNSC, LIHC, READ and COAD. The KIRC box plot shows higher TH2LCRR RNA expression in tumor versus normal tissue (log2 FC = +0.177, t-test p < 0.001).
This table shows molecular features associated with TH2LCRR in patient tissues and cancer cell lines. In patient samples, TH2LCRR shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
